Centene Corporation exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the company shows strong top-line revenue growth of 23.2%, this is completely offset by a catastrophic YoY EPS decline of -248.7% and a deeply negative ROE of -28.68%. The stock appears cheap on a Price-to-Sales (0.12) and Price-to-Book (1.07) basis, but these metrics likely reflect a 'value trap' given the negative profit margins and lack of earnings stability. Despite a recent short-term price rally, the long-term technical trend remains bearish and analyst targets are flat.